ClinicalTrials.gg
TerminatedNCT03586869Updated Aug 27, 2024Results posted

QUILT-3.080: NANT Pancreatic Cancer Vaccine

A Phase 1/2 interventional study of Aldoxorubicin HCl and ALT-803 in Pancreatic Cancer, sponsored by ImmunityBio, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by ImmunityBio, Inc. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Pancreatic Neoplasms by ImmunityBio, Inc. — none open to participants now, 1 under way, none of them phase 3. Pancreatic Neoplasms · ImmunityBio, Inc..

Enrollment
11th of 15
3 · median 15
Started
2018
with 1 other
Phase 1/2
8 of 15
none open now
Registered
12th of 15
by date

Among the 15 studies in Pancreatic Neoplasms by ImmunityBio, Inc., this one is the 11th largest by enrollment, is one of 2 that started in 2018, is one of 8 in phase 1/2, and was the 12th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

None of the 15 studies in Pancreatic Neoplasms by ImmunityBio, Inc. is open now. The open studies under Pancreatic Neoplasms, anywhere →

Who these studies take

Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Pancreatic Neoplasms by ImmunityBio, Inc. as a file.
02

Study summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care (SoC) chemotherapy.

Read the detailed description

Treatment will be administered in two phases, an induction and a maintenance phase, as described below. Subjects will continue induction treatment for up to 1 year. Treatment in the study will be discontinued if the subject experiences progressive disease (PD) or unacceptable toxicity (not corrected with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the subject's best interest to continue treatment. Those who have a complete response (CR) in the induction phase will enter the maintenance phase of the study. Subjects who experience ongoing stable disease (SD) or an ongoing partial response (PR) at 1 year may enter the maintenance phase at the Investigator's discretion. Subjects may remain on the maintenance phase of the study for up to 1 year. Treatment will continue in the maintenance phase until the subject experiences PD or unacceptable toxicity (not corrected with dose reduction), withdraws consent, or if the Investigator feels it is no longer in the subject's best interest to continue treatment. The maximum time on study treatment, including both the induction and maintenance phases, is 2 years.

03

Conditions studied

  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old.
  2. Able to understand and provide a signed that fulfills the relevant IRB or Independent Ethics Committee (IEC) guidelines.
  3. -confirmed pancreatic adenocarcinoma with progression on or after SoC therapy.
  4. performance status of 0 to 2.
  5. Have at least 1 of ≥ 1.0 cm.
  6. Must have a recent formalin-fixed, paraffin-embedded (FFPE) tumor specimen following the conclusion of the most recent anticancer treatment and be willing to release the specimen for prospective and exploratory tumor molecular profiling. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period, if considered safe by the Investigator. If safety concerns preclude collection of a biopsy during the screening period, a tumor biopsy specimen collected prior to the conclusion of the most recent anticancer treatment may be used.
  7. Must be willing to provide blood samples prior to the start of treatment on this study for prospective tumor molecular profiling and exploratory analyses.
  8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of treatment for exploratory analyses, if considered safe by the Investigator.
  9. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
  10. Agreement to practice effective for female subjects of and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non- sterile male subjects must agree to use a condom for up to 4 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, IUDs, and abstinence.

Exclusion criteria

Exclusion Criteria:

  1. Serious uncontrolled concomitant disease that would contraindicate the use of the drug used in this study or that would put the subject at high risk for treatment-related complications.
  2. Systemic disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma).
  3. History of organ transplant requiring .
  4. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
  5. Inadequate organ function, evidenced by the following laboratory results:

    1. \< 1,000 cells/mm3.
    2. count \< 75,000 cells/mm3.
    3. Total greater than the (ULN; unless the subject has documented Gilbert's syndrome).
    4. (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 2.5 × ULN (> 5 × ULN in subjects with liver ).
    5. Alkaline phosphatase levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases).
    6. Serum creatinine > 2.0 mg/dL or 177 μmol/L.
    7. Serum anion gap > 16 mEq/L or arterial blood with pH \< 7.3.
    8. Medically uncorrectable grade 3 anemia ( \< 8 g/dL).
  6. Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with uncontrolled hypertension should be medically managed on a stable regimen to control hypertension prior to study entry.
  7. Serious myocardial dysfunction defined by ECHO as absolute (LVEF) 10% below the institution's lower limit of predicted normal.
  8. Dyspnea at rest due to complications of advanced or other disease requiring continuous oxygen therapy.
  9. Positive results of screening test for (HIV).
  10. Current chronic daily treatment (continuous for > 3 months) with systemic (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.
  11. Known to any component of the study medication(s).
  12. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.
  13. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study day 1.
  14. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8 inducer (rifampin) within 14 days before study day 1.
  15. Participation in an investigational drug study or history of receiving any investigational treatment within 14 days prior to initiation of treatment on this study, except for receipt of testosterone-lowering therapy in men with prostate cancer, or treatment with any NANT Cancer Vaccine therapy.
  16. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  17. Concurrent participation in any interventional clinical trial.
  18. Pregnant and nursing women.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    NANT Pancreatic Cancer Vaccine

    A combination of agents were administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011 (CEA), ETBX-021 (HER2), ETBX-051 (Brachyury), ETBX-061 (MUC1), GI-4000, GI-6207, GI-6301, haNK for infusion, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, oxaliplatin, and Stereotactic Body Radiation Therapy (SBRT).

    Drug: Aldoxorubicin HCl · Biological: ALT-803 · Biological: ETBX-011 · Biological: ETBX-021 · Biological: ETBX-051 · Biological: ETBX-061 · Biological: GI-4000 · Biological: GI-6207 · Biological: GI-6301 · Biological: haNK for infusion · Biological: bevacizumab · Drug: Capecitabine · Drug: Cyclophosphamide · Drug: Fluorouracil · Drug: Leucovorin · Drug: nab-Paclitaxel · Drug: Oxaliplatin · Biological: Avelumab · Procedure: SBRT

Interventions

  • Aldoxorubicin Hydrochloride

  • BiologicalALT-803

    Recombinant human super agonist interleukin-15 (IL-15) complex

  • BiologicalETBX-011

    Ad5 \[E1-, E2b-\]-CEA

  • BiologicalETBX-021

    Ad5 \[E1-, E2b-\]-HER2

  • BiologicalETBX-051

    Ad5 \[E1-, E2b-\]-Brachyury

  • BiologicalETBX-061

    Ad5 \[E1-, E2b-\]-MUC1

  • BiologicalGI-4000

    RAS yeast

  • BiologicalGI-6207

    Carcinoembryonic Antigen (CEA) yeast

  • BiologicalGI-6301

    Brachyury yeast

  • BiologicalhaNK for infusion

    NK-92 \[CD16.158V, ER IL-2\]

  • Biologicalbevacizumab

    Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal

  • 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

  • 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

  • 5-fluoro-2,4 (1H,3H)-pyrimidinedione

  • L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

  • Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

  • cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum

  • BiologicalAvelumab

    Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody

  • ProcedureSBRT

    Stereotactic Body Radiation Therapy

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)

    Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03

    Time frame: Up to 230 days

Secondary outcomes

  1. Objective Response Rate by RECIST Version 1.1

    Tumors were assessed at screening, and tumor response will be assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase by computed tomography (CT) or magnetic resonance imaging (MRI) of target and non-target lesions in accordance with RECIST Version 1.1. An objective response is defined as a confirmed complete or partial overall response with confirmation occurring at least 4 weeks after the initial response is observed.

    Time frame: Tumors were assessed at screening, and tumor response will be assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase until disease progression, up to 6.8 months

  2. Objective Response Rate by irRC

    Tumors were assessed at screening, and tumor response will be assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase by computed tomography (CT) or magnetic resonance imaging (MRI) of target and non-target lesions in accordance with immune-related response criteria (irRC). An objective response is defined as a confirmed complete or partial overall response with confirmation occurring at least 4 weeks after the initial response is observed.

    Time frame: Tumors were assessed at screening, and tumor response will be assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase until confirmed disease progression, up to 6.8 months

  3. Progression Free Survival by RECIST Version 1.1.

    PFS was evaluated using Kaplan-Meier methods. PFS was defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first. Subjects completing study follow-up or initiating a new anticancer therapy prior to documented PD was censored in the PFS analysis at the last known date the subject was progression free prior to completing follow-up or initiating the new therapy.

    Time frame: Tumors were assessed at screening, and tumor response was assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase until disease progression or death (any cause) whichever occurred first, up to 6.8 months.

  4. Progression Free Survival by irRC

    PFS was evaluated using Kaplan-Meier methods. PFS was defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first. Subjects completing study follow-up or initiating a new anticancer therapy prior to documented PD was censored in the PFS analysis at the last known date the subject was progression free prior to completing follow-up or initiating the new therapy.

    Time frame: Tumors were assessed at screening, and tumor response was assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase until disease progression or death (any cause) whichever occurred first.

  5. Overall Survival

    OS was evaluated using Kaplan-Meier methods. OS was defined as the time from the date of first treatment to the date of death (any cause). Participants who were alive at the end of follow-up were censored in the OS analysis at the last known date alive.

    Time frame: Participants were assessed from screening to death.

  6. Duration of Response (DOR) by RECIST Version 1.1 and irRC

    DOR was be defined as the time from the date of first response (PR or CR) to the date of disease progression or death (any cause) whichever occurs first. Responding subjects completed study follow-up or initiating a new anticancer therapy prior to documented PD were censored in the DOR analysis at the last known date the subject was progression free prior completing follow-up or initiating the new therapy.

    Time frame: Tumors were assessed at screening, and tumor response will be assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase until confirmed disease progression, up to 6.8 months

  7. Disease Control Rate (Confirmed Complete Response, Partial Response, or Stable Disease Lasting for at Least 2 Months) by RECIST Version 1.1 and irRC

    Disease control is defined as subjects with a confirmed CR, PR, or SD lasting for at least 2 months.

    Time frame: Tumors were assessed at screening, and tumor response will be assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase until confirmed disease progression, up to 6.8 months

  8. Quality of Life by Patient Reported Outcomes (PRO)

    PROs were assessed using the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep is compilation of general questions divided into five QOL subscales: Physical Well-Being - Scores ranging from 0-28 Social/Family Well-Being - Scores ranging from 0-28 Emotional Well-Being - Scores ranging from 0-24 Functional Well-Being - Scores ranging from 0-28 Additional Concerns - Scores ranging from 0-72 It uses 5-point Likert-type response categories ranging from 0 = 'not at all' to 4 = 'very much' The higher scales and subscales indicate better quality of life. Negatively worded items were reverse scored. If the missing for each subscale was less than 50%, the prorating scores were computed for the subscale.

    Time frame: 30 days after last dose, up 12.7 months

07

Results

Posted Aug 27, 2024

Participant flow

Participant flow — Overall Study
MilestoneNANT Pancreatic Cancer Vaccine
Started3
Completed0
Not completed3
Withdrew: Progressive disease3

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)

Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03

Time frame:
Up to 230 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)
ParticipantsNANT Pancreatic Cancer Vaccine
Treatment-Emergent Adverse Events3
Treatment-Emergent Serious Adverse Events2
SecondaryObjective Response Rate by RECIST Version 1.1

Tumors were assessed at screening, and tumor response will be assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase by computed tomography (CT) or magnetic resonance imaging (MRI) of target and non-target lesions in accordance with RECIST Version 1.1. An objective response is defined as a confirmed complete or partial overall response with confirmation occurring at least 4 weeks after the initial response is observed.

Time frame:
Tumors were assessed at screening, and tumor response will be assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase until disease progression, up to 6.8 months
Reported as:
Count of participants · Participants
Objective Response Rate by RECIST Version 1.1
ParticipantsNANT Pancreatic Cancer Vaccine
Objective Response Rate by RECIST Version 1.10
SecondaryObjective Response Rate by irRC

Tumors were assessed at screening, and tumor response will be assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase by computed tomography (CT) or magnetic resonance imaging (MRI) of target and non-target lesions in accordance with immune-related response criteria (irRC). An objective response is defined as a confirmed complete or partial overall response with confirmation occurring at least 4 weeks after the initial response is observed.

Time frame:
Tumors were assessed at screening, and tumor response will be assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase until confirmed disease progression, up to 6.8 months
Reported as:
Count of participants · Participants
Objective Response Rate by irRC
ParticipantsNANT Pancreatic Cancer Vaccine
Objective Response Rate by irRC0
SecondaryProgression Free Survival by RECIST Version 1.1.

PFS was evaluated using Kaplan-Meier methods. PFS was defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first. Subjects completing study follow-up or initiating a new anticancer therapy prior to documented PD was censored in the PFS analysis at the last known date the subject was progression free prior to completing follow-up or initiating the new therapy.

Time frame:
Tumors were assessed at screening, and tumor response was assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase until disease progression or death (any cause) whichever occurred first, up to 6.8 months.
Reported as:
Median · Months
Progression Free Survival by RECIST Version 1.1.
MonthsNANT Pancreatic Cancer Vaccine
Progression Free Survival by RECIST Version 1.1.1.7 (0.5 to NA)
SecondaryProgression Free Survival by irRC

PFS was evaluated using Kaplan-Meier methods. PFS was defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first. Subjects completing study follow-up or initiating a new anticancer therapy prior to documented PD was censored in the PFS analysis at the last known date the subject was progression free prior to completing follow-up or initiating the new therapy.

Time frame:
Tumors were assessed at screening, and tumor response was assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase until disease progression or death (any cause) whichever occurred first.
Reported as:
Median · Months
Progression Free Survival by irRC
MonthsNANT Pancreatic Cancer Vaccine
Progression Free Survival by irRC1.7 (0.5 to NA)
SecondaryOverall Survival

OS was evaluated using Kaplan-Meier methods. OS was defined as the time from the date of first treatment to the date of death (any cause). Participants who were alive at the end of follow-up were censored in the OS analysis at the last known date alive.

Time frame:
Participants were assessed from screening to death.
Reported as:
Median · Months
Overall Survival
MonthsNANT Pancreatic Cancer Vaccine
Overall Survival4.6 (2.5 to NA)
SecondaryDuration of Response (DOR) by RECIST Version 1.1 and irRC

DOR was be defined as the time from the date of first response (PR or CR) to the date of disease progression or death (any cause) whichever occurs first. Responding subjects completed study follow-up or initiating a new anticancer therapy prior to documented PD were censored in the DOR analysis at the last known date the subject was progression free prior completing follow-up or initiating the new therapy.

Time frame:
Tumors were assessed at screening, and tumor response will be assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase until confirmed disease progression, up to 6.8 months

No measurements were reported for this outcome.

SecondaryDisease Control Rate (Confirmed Complete Response, Partial Response, or Stable Disease Lasting for at Least 2 Months) by RECIST Version 1.1 and irRC

Disease control is defined as subjects with a confirmed CR, PR, or SD lasting for at least 2 months.

Time frame:
Tumors were assessed at screening, and tumor response will be assessed every 8 weeks during the induction phase, and every 12 weeks during the maintenance phase until confirmed disease progression, up to 6.8 months
Reported as:
Count of participants · Participants
Disease Control Rate (Confirmed Complete Response, Partial Response, or Stable Disease Lasting for at Least 2 Months) by RECIST Version 1.1 and irRC
ParticipantsNANT Pancreatic Cancer Vaccine
Complete Response0
Partial Response0
Stable Disease1
SecondaryQuality of Life by Patient Reported Outcomes (PRO)

PROs were assessed using the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep is compilation of general questions divided into five QOL subscales: Physical Well-Being - Scores ranging from 0-28 Social/Family Well-Being - Scores ranging from 0-28 Emotional Well-Being - Scores ranging from 0-24 Functional Well-Being - Scores ranging from 0-28 Additional Concerns - Scores ranging from 0-72 It uses 5-point Likert-type response categories ranging from 0 = 'not at all' to 4 = 'very much' The higher scales and subscales indicate better quality of life. Negatively worded items were reverse scored. If the missing for each subscale was less than 50%, the prorating scores were computed for the subscale.

Time frame:
30 days after last dose, up 12.7 months
Reported as:
Median · score on a scale
Quality of Life by Patient Reported Outcomes (PRO)
score on a scaleNANT Pancreatic Cancer Vaccine
Physical Well-Being - Baseline13.3 (11.7 to 15.0)
Physical Well-Being - (I) C3D116.5 (14.0 to 19.0)
Physical Well-Being - (I) C5D19.0 (9.0 to 9.0)
Physical Well-Being - (I) C7D111.0 (11.0 to 11.0)
Physical Well-Being - (I) C9D13.0 (3.0 to 3.0)
Physical Well-Being - (M) C1D112.0 (12.0 to 12.0)
Physical Well-Being - End of Treatment22.0 (22.0 to 22.0)
Social/Family Well-Being - Baseline25.5 (23.0 to 28.0)
Social/Family Well-Being- (I) C3D126.0 (24.0 to 28.0)
Social/Family Well-Being- (I) C5D120.0 (20.0 to 20.0)
Social/Family Well-Being - (I) C7D125.0 (25.0 to 25.0)
Social/Family Well-Being - (I) C9D123.0 (23.0 to 23.0)
Social/Family Well-Being - (M) C1D118.0 (18.0 to 18.0)
Social/Family Well-Being - End of Treatment28.0 (28.0 to 28.0)
Emotional Well-Being - Baseline19.0 (16.0 to 22.0)
Emotional Well-Being - (I) C3D120.5 (19.0 to 22.0)
Emotional Well-Being - (I) C5D118.0 (18.0 to 18.0)
Emotional Well-Being - (I) C7D114.0 (14.0 to 14.0)
Emotional Well-Being - (I) C9D113.0 (13.0 to 13.0)
Emotional Well-Being - (M) C1D18.0 (8.0 to 8.0)
Emotional Well-Being - End of Treatment21.0 (21.0 to 21.0)
Functional Well-Being - Baseline15.0 (8.0 to 22.0)
Functional Well-Being - (I) C3D118.0 (15.0 to 21.0)
Functional Well-Being - (I) C5D117.0 (17.0 to 17.0)
Functional Well-Being - (I) C7D112.0 (12.0 to 12.0)
Functional Well-Being - (I) C9D19.0 (9.0 to 9.0)
Functional Well-Being - (M) C1D110.0 (10.0 to 10.0)
Functional Well-Being - End of Treatment20.0 (20.0 to 20.0)
Additional Concerns - Baseline42.4 (36.0 to 49.0)
Additional Concerns - (I) C3D141.3 (36.0 to 46.6)
Additional Concerns - (I) C5D142.0 (42.0 to 42.0)
Additional Concerns - (I) C7D132.0 (32.0 to 32.0)
Additional Concerns - (I) C9D133.0 (33.0 to 33.0)
Additional Concerns - (M) C1D140.0 (40.0 to 40.0)
Additional Concerns - End of Treatment47.0 (47.0 to 47.0)

Adverse events

Collected over Non-serious AEs were followed for 30 days after the subject's last dose of study treatment, up to 230 days. Non-serious grade 3 or 4 AEs were followed until resolution or stabilization, up to 230 days. All SAEs that had not resolved upon discontinuation of the subject's participation in the study were followed until recovered, recovered with sequelae, not recovered (death due to other cause), death (due to the SAE), lost to follow-up, up to 230 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NANT Pancreatic Cancer Vaccine3/3 (100%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventNANT Pancreatic Cancer Vaccine
Febrile neutropeniaBlood and lymphatic system disorders1/3
Disease progressionGeneral disorders1/3
Clostridium difficile infectionInfections and infestations1/3
Most frequent other events
Showing 10 of 34
Most frequent other events
EventNANT Pancreatic Cancer Vaccine
FatigueGeneral disorders3/3
Disease progressionGeneral disorders2/3
PyrexiaGeneral disorders2/3
AnaemiaBlood and lymphatic system disorders2/3
NeutropeniaBlood and lymphatic system disorders2/3
NauseaGastrointestinal disorders2/3
Deep vein thrombosisVascular disorders2/3
Catheter site haemorrhageGeneral disorders1/3
ChillsGeneral disorders1/3
Gait disturbanceGeneral disorders1/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)NANT Pancreatic Cancer Vaccine
Mean67.3 ± 5.77
Sex: Female, Male
Sex: Female, Male(Participants)NANT Pancreatic Cancer Vaccine
Female0
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NANT Pancreatic Cancer Vaccine
Hispanic or Latino0
Not Hispanic or Latino2
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NANT Pancreatic Cancer Vaccine
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White3
More than one race0
Unknown or Not Reported0
subjects with pancreatic cancer who have progressed on or after standard-of-care therapy
subjects with pancreatic cancer who have progressed on or after standard-of-care therapy(Participants)NANT Pancreatic Cancer Vaccine
Count of participants3
08

Study locations

1 site
  • Chan Soon-Shiong Institute for Medicine
    El Segundo, California 90245, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Apr 2019, 9 months.

Results were first posted in Aug 2024, 5 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2018
First posted
Jul 16, 2018
StartActual
Jul 17, 2018
Primary completionActual
Apr 17, 2019
CompletionActual
Aug 1, 2019
Results first posted
Aug 27, 2024
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03586869
Lead sponsor
ImmunityBio, Inc.
Responsible party
Sponsor
First posted
Jul 16, 2018
Start date
Jul 17, 2018
Primary completion
Apr 17, 2019
Completion
Aug 1, 2019
Results posted
Aug 27, 2024
Last update
Aug 27, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nogapendekin alfa inbakicept · ETBX-011 · ETBX-021 · ETBX-051 · ETBX-061 · GI-4000 · Yeast-CEA vaccine · GI-6301

Start the discussion